Crossmark

Comparing the efficacy and safety of the ABC-14 regimen (azacitidine, venetoclax, and chidamide) with traditional “3 + 7” intensive induction regimen or AB-14 regimen (venetoclax combined with azacitidine) in newly diagnosed AML: study protocol for a prospective, multicenter, randomized, open-label clinical trial

Crossref DOI link: https://doi.org/10.1186/s13063-025-09339-y

Published Online: 2025-12-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yan, Honghong

Huang, Xin

Wu, Ping

Deng, Chengxin

Li, Minming

Lai, Peilong

Du, Xin

Weng, Jianyu https://orcid.org/0000-0001-5446-292X
Funding

Funding for this research was provided by:

Shenzhen Chipscreen Biosciences Co., Ltd (F24000852)

Shenzhen Chipscreen Biosciences Co., Ltd (F24003871)
License Information

Text and Data Mining valid from 2025-12-10

Version of Record valid from 2026-01-14
More Information

Article History

Received: 9 May 2025

Accepted: 22 November 2025

First Online: 10 December 2025

Change Date: 1 February 2026

Change Type: Update

Change Details: The funding section has been updated.

Declarations

:

: The Ethics Committee of Guangdong Provincial People’s Hospital has approved the trial protocol (version 1.0—01 Jun 2023), with an ethics approval number of KY2023-1057–03. Written informed consent to participate will be obtained from all study participants. The principal investigator will ensure that the study is conducted in accordance with the protocol and complies with ICH Good Clinical Practice Guidelines, the Helsinki Declaration, and all regulatory and institutional requirements.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below